The Semaglutide Treatment Effect in People With Obesity: a Review
Year: 2025
Type: article
Abstract: ABSTRACT Background: Over 200 consequences, such as type 2 diabetes, cardiovascular disease, and shortened life expectancy, are linked to obesity, a chronic worldwide health issue. The effectiveness of current pharmaceutical weight-management treatments has been found to be limited. A glucagon-like peptide-1 (GLP-1) receptor agonist called semaglutide has shown promise as a therapy for overweight and obesity. Methods: Evidence from the Semaglutide Treatment Effect in People with Obesity is compiled in this review. We conducted a structured narrative review to summarize the current evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with obesity. Relevant studies were identified through a comprehensive search of PubMed, Embase and Scopus, using the keywords GLP-1 receptor agonists, semaglutide, safety, adverse events and obesity. Conclusion: Semaglutide 2.4 mg used once a week is a safe and efficient way for adults who are overweight or obese to manage their weight over time. Its strong effectiveness, cardiometabolic advantages, and manageable safety profile make it a revolutionary pharmaceutical treatment for obesity.
Author: Tulsi Singh*1, Sonalal Prasad Kushwaha1, Gireesh Saini2
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7107878935
FWCI:
Cites:
Cited by:
Related to: